Articles | Volume 5, issue 1
https://doi.org/10.7150/jbji.40333
https://doi.org/10.7150/jbji.40333
Original full-length article
 | 
10 Feb 2020
Original full-length article |  | 10 Feb 2020

Duration of rifampin therapy is a key determinant of improved outcomes in early-onset acute prosthetic joint infection due to Staphylococcus treated with a debridement, antibiotics and implant retention (DAIR): a retrospective multicenter study in France

A. Becker, L. Kreitmann, C. Triffaut-Fillit, F. Valour, E. Mabrut, E. Forestier, O. Lesens, C. Cazorla, S. Descamps, B. Boyer, C. Chidiac, S. Lustig, E. Montbarbon, C. Batailler, and T. Ferry

Cited articles

Zimmerli W, Widmer AF, Blatter M, Frei R, Ochsner PE. Role of rifampin for treatment of orthopedic implant-related staphylococcal infections: a randomized controlled trial. Foreign-Body Infection (FBI) Study Group. JAMA. 20 mai. 1998;279(19):1537–41.
Osmon DR, Berbari EF, Berendt AR, Lew D, Zimmerli W, Steckelberg JM. et al. Diagnosis and management of prosthetic joint infection: clinical practice guidelines by the Infectious Diseases Society of America. Clin Infect Dis Off Publ Infect Dis Soc Am. janv. 2013;56(1):e1–25.